SCHEMBL370600

SCHEMBL370600

COc1ccc(Cn2cc(C(=O)N(C)OC)c(C(C)(C)O)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 10/20 0.43
CACNA1G O43497 2/20 0.40
CACNA1H O95180 2/20 0.40
CACNA1I Q9P0X4 2/20 0.40
KMT2A Q03164 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
AADAT Q8N5Z0 1/20 0.39
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
PDE1A P54750 1/20 0.38
PDE1B Q01064 1/20 0.38
PDE1C Q14123 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
TSPO P30536 1/20 0.37
HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370679 0.84 L3MBTL1 (0.44) KLKB1CACNA1GCACNA1HCACNA1IKMT2A
SCHEMBL370299 0.83 AADAT (0.43) KLKB1CACNA1GCACNA1HCACNA1IKMT2A
SCHEMBL2537359 0.83 CACNA1G (0.42) KLKB1CACNA1GCACNA1HCACNA1IKMT2A
SCHEMBL368611 0.83 CACNA1G (0.42) KLKB1CACNA1GCACNA1HCACNA1IKMT2A
SCHEMBL369528 0.82 KMT2A (0.43) KLKB1CACNA1GCACNA1HCACNA1IKMT2A
SCHEMBL369221 0.82 CACNA1G (0.41) KLKB1CACNA1GCACNA1HCACNA1IKMT2A
SCHEMBL368790 0.82 KLKB1 (0.47) KLKB1AADAT
SCHEMBL369521 0.81 CACNA1G (0.43) KLKB1CACNA1GCACNA1HCACNA1IKMT2A
SCHEMBL369607 0.80 KLKB1 (0.47) KLKB1CACNA1GCACNA1HCACNA1IKMT2A
SCHEMBL369366 0.80 CACNA1G (0.40) KLKB1CACNA1GCACNA1HCACNA1IKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 KLKB1 4667/4885CACNA1G 353/4885CACNA1H 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.